Finasteride 10-Year Results: What Happens If You Stay on It for a Decade

The longest continuous finasteride study tracked 532 men for 10 years. The results challenge assumptions about both efficacy and safety.

Most finasteride studies run 1–2 years. A few go to 5. The Yanagisawa study went to 10 — following 532 Japanese men taking finasteride 1mg daily for a full decade. It's the longest continuous safety and efficacy dataset we have, and it answers the question every man on finasteride eventually asks: what happens if I stay on this forever?

Efficacy: It Keeps Working — and Improving

The most important finding from the 10-year data is that finasteride's benefits don't plateau at year 1 or 2. They continue to accumulate over the full study period.

At 10 years, 99.1% of participants showed either improvement or prevention of progression. That's not a typo — 99.1%. Only 0.9% of men continued to progress despite a decade of treatment.

Even more remarkably, improvement continued between year 5 and year 10 (p<0.001). Most hair loss treatments show diminishing returns over time. Finasteride showed the opposite — continued gains across the full decade.

The Merck 5-year trial showed a similar trajectory on a shorter timeline: 48% improvement at 1 year climbing to 66% at 4 years. The Japanese 10-year data extends this curve further.

Safety: No Accumulating Risks

The safety profile over 10 years was remarkably clean. The overall adverse reaction rate was 6.8% across the entire study period. Every adverse reaction documented was classified as mild. There were zero serious adverse reactions. Not a single one over ten years.

This matters because one of the most common fears about finasteride is that long-term DHT suppression might produce accumulating damage — that side effects might get worse over time, or that new problems might emerge after years of use. The 10-year data directly contradicts this fear.

The PLESS trial's 5-year data told the same story from a different angle: sexual side effects actually decreased over time, dropping to ≤0.3% incidence by year 5 — essentially indistinguishable from placebo.

What Happens If You Stop After Years of Use

This is the other question long-term users eventually ask. The answer is consistent across all studies: when you stop finasteride, DHT returns to baseline within approximately 14 days. Hair loss resumes. Within 12 months of discontinuation, you lose the gains you made.

This isn't because finasteride is "addictive" or because it makes your hair loss worse. It's because the underlying condition — DHT-driven follicle miniaturization — never went away. Finasteride was holding it in check. Remove the brake, and the process resumes where it left off.

For men who have been on finasteride for 5+ years, this creates a practical consideration: you've accumulated years of protection and possibly improvement. Stopping means losing that progress. This is worth weighing against any reason you might be considering discontinuation.

The 10-Year Cost Perspective

At generic pricing ($3–7/month), 10 years of finasteride costs roughly $360–$840 total. That's less than a single hair transplant consultation. For a medication that maintains and improves hair over a full decade, the cost-effectiveness is extraordinary.

Even at telehealth-bundled pricing ($15–25/month), a decade of treatment runs $1,800–$3,000 — still a fraction of surgical alternatives and with significantly less risk.

Who Benefits Most From Long-Term Use

Early starters. Men who begin at Norwood I–III have the most follicles to protect and the strongest response rates. Starting early and staying on treatment produces the best 10-year outcomes.

Consistent users. The benefits require consistent daily use. Intermittent dosing (every other day, weekdays only) may maintain some DHT suppression but hasn't been studied over 10-year timeframes.

Men 25–45. This demographic has the most to gain from proactive long-term treatment — enough remaining hair to protect, enough remaining life to benefit from the protection, and low enough risk of age-related health changes that confound the picture.